A Deeper Look into Immunoglobulin Replacement in the Management of Primary Immunodeficiency Diseases (PIDD): Individualizing Treatment for Improved Clinical and Economic Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

Optimizing Clinical and Economic Outcomes in the Management of Primary Immunodeficiency
Diseases (PIDD): What Managed Care Needs to Know About Immunoglobulin Replacement
Therapy is a 3-part live webinar series that will provide attendees with the latest information in the management of PIDD

This is Part 1 of the series focusing on individualizing treatment for
improved clinical and economical outcomes

This activity is an archive from the webinar held December 4, 2019

This activity is valid from January 1, 2020 to January 1, 2022

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
CSL Behring

Primary immunodeficiency diseases (PIDD) are a group of more than 300 rare, chronic disorders in which part of the body's immune system is missing or functions improperly. While not contagious, these diseases are caused by hereditary or genetic defects, and, although some disorders present at birth or in early childhood, the disorders can affect anyone, regardless of age or gender. Fortunately for patients with PIDD, the treatment paradigm has exploded in the past 10 years, giving HCPs many more options in managing the patient population. This live webinar series will feature strategies to overcome challenges in the optimal treatment of PIDD, updates on immunoglobulin replacement therapies, and practical managed care approaches to provide cost-effective solutions to improve both clinical and economic outcomes.

Upon completion of this activity, participants will be able to:

  • Identify patients who may have a primary immunodeficiency disease (PIDD) and discuss appropriate tests to diagnose the disease

  • Examine the history of immunoglobulin (Ig) therapy in PIDD and its rationale for use

  • Compare and contrast the different immunoglobulin products and their FDA-approved indications, sodium and sugar contents, and adverse effects

  • Differentiate the key differences between subcutaneous and intravenous therapy, including the advantages and disadvantages of both options in various patient populations

Faculty: Jordan S. Orange MD, PhD
Reuben S. Carpentier Professor and Chairman
Department of Pediatrics, Vagelos College of Physicians and Surgeons
Columbia University
Pediatrician In-Chief, Morgan Stanley Children’s Hospital


Dr. Orange serves as a consultant for Enzyvant and Takeda. He previously served as a scientific advisory board member for ADMA Biologics. He is an Author/Editor for UpToDate. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
CSL Behring

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue